Back to top
more

Incyte Corporation (INCY)

(Delayed Data from NSDQ)

$80.50 USD

80.50
1,318,864

-0.12 (-0.15%)

Updated Jan 17, 2020 03:56 PM ET

Add to portfolio

4-Sell       4  

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.66%
17.94%
9.57%
5.30%
2.19%
10.75%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

C Value | A Growth | B Momentum | A VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Zacks News

Zacks Equity Research

Incyte (INCY) Stock Sinks As Market Gains: What You Should Know

Incyte (INCY) closed at $76.53 in the latest trading session, marking a -0.79% move from the prior day.

INCY

Zacks Equity Research

Incyte's Application for Pemigatinib Gets EMA's Validation

The EMA endorses Incyte's (INCY) MAA for pemigatinib to treat locally advanced/metastatic cholangiocarcinoma with a FGFR2 fusion that is relapsed or refractory post minimum one line of systemic therapy.

AGIO EBS INCY ALXN

Zacks Equity Research

Biotech Stock Roundup: Updates From INCY & EXEL, APLS & LIFE Surge on Positive Data

A low-key week for the biotech sector, with a few pipeline and regulatory updates.

LIFE INCY EXEL APLS

Zacks Equity Research

Company News For Jan 6, 2020

Companies In The News Are: CANF, LW, INCY, NOVN

LW INCY NOVN CANF

Zacks Equity Research

Incyte's (INCY) Itacitinib Fails in Late-Stage GVHD Study

Incyte (INCY) fails to meet goals in the phase III study on itacitinib for the treatment of first-line acute GVHD.

MRK NVS INCY ALXN

Zacks Equity Research

Incyte (INCY) Stock Moves -0.44%: What You Should Know

In the latest trading session, Incyte (INCY) closed at $88.39, marking a -0.44% move from the previous day.

INCY

Zacks Equity Research

Incyte (INCY) Surges 44% YTD on Jakafi's Strong Performance

Incyte (INCY) outperforms the industry year to date on strong Jakafi sales.

LLY NVS ALXN INCY

Zacks Equity Research

Has Incyte (INCY) Outpaced Other Medical Stocks This Year?

Is (INCY) Outperforming Other Medical Stocks This Year?

INCY

Zacks Equity Research

Incyte (INCY) Stock Sinks As Market Gains: What You Should Know

Incyte (INCY) closed at $90.10 in the latest trading session, marking a -1.14% move from the prior day.

INCY

Ekta Bagri

Biotech Stock Outlook: M&A Activity Retains Growth Streak

The biotech sector enjoys a good run in 2019 on the back of the M&A activities and positive pipeline updates underway. We expect this momentum to stay in 2020 as well.

VRTX REGN INCY GILD ANIK ALXN ACAD

Zacks Equity Research

Here's Why Momentum Investors Will Love Incyte (INCY)

Does Incyte (INCY) have what it takes to be a top stock pick for momentum investors? Let's find out.

INCY

Zacks Equity Research

Moving Average Crossover Alert: Incyte

Incyte is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

INCY

Zacks Equity Research

Biotech Stock Roundup: Pipeline Updates From BIIB, AXSM, CARA, Collaborations & More

Key highlights of the past week include regulatory and pipeline updates along with collaboration deals.

MRK SGEN CARA BIIB AXSM INCY

Zacks Equity Research

Why Is Incyte (INCY) Up 12.5% Since Last Earnings Report?

Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

INCY

Zacks Equity Research

Incyte's NDA for Pemigatinib Gets FDA's Priority Review Tag

The FDA accepts and grants priority review to Incyte's (INCY) new drug application for pemigatinib as a second-line treatment for patients with FGFR2 translocated cholangiocarcinoma.

AGIO INCY VRTX ANIK

Zacks Equity Research

Merck's Keytruda Gets Nod in China for Difficult Lung Cancer

Merck (MRK) receives the third approval of Keytruda for first-line non-small cell lung cancer patient population in China.

MRK PFE INCY AMGN

Zacks Equity Research

Merck's Keytruda Wins EU Nod for First-Line Head/Neck Cancer

Merck's (MRK) Keytruda gets approval in Europe to treat first-line head/neck cancer based on data from the phase III KEYNOTE-048 study.

MRK PFE INCY AMGN

Zacks Equity Research

Incyte (INCY) Is Up 1.88% in One Week: What You Should Know

Does Incyte (INCY) have what it takes to be a top stock pick for momentum investors? Let's find out.

INCY

Zacks Equity Research

The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Vertex Pharmaceuticals, Incyte and Regeneron Pharmaceuticals

The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Vertex Pharmaceuticals, Incyte and Regeneron Pharmaceuticals

INCY REGN VRTX ALXN

Zacks Equity Research

4 Big Biotech Stocks Worth Considering Post Q3 Earnings

We highlight a few principal players from the biotech sector, which are likely to witness a winning run in the near term.

BMY VRTX AMGN REGN INCY BIIB ALXN

Zacks Equity Research

The Zacks Analyst Blog Highlights: Coherus, Incyte, ACADIA and Celgene

The Zacks Analyst Blog Highlights: Coherus, Incyte, ACADIA and Celgene

ACAD CHRS CELG INCY

Zacks Equity Research

4 Biotech Stocks That Could Keep Beating Wall Street

The biotechnology industry has lagged the broader market so far this year, but these four stocks have done pretty well and should continue to do so.

BMY LLY ACAD CHRS CELG BIIB INCY ADPT ALEC NGM TAK

Zacks Equity Research

Will Incyte (INCY) Gain on Rising Earnings Estimates?

Incyte (INCY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

INCY

Zacks Equity Research

The Zacks Analyst Blog Highlights: Sony, Allstate and Incyte

The Zacks Analyst Blog Highlights: Sony, Allstate and Incyte

SNE ALL INCY

John Blank

Earnings Season Clean Up: Global Week Ahead

71% of S&P 500 members have reported Q3 results. At Zacks, 'total earnings means 'aggregate net income' for those 357 S&P 500 members -- not mean, median or market-cap weighted EPS.

SNE ALL INCY